Nuzhat Ahmed

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1619071/publications.pdf

Version: 2024-02-01

50 papers	4,105 citations	147566 31 h-index	205818 48 g-index
50 all docs	50 docs citations	50 times ranked	5986 citing authors

#	Article	IF	Citations
1	Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research. Frontiers in Oncology, 2013, 3, 256.	1.3	358
2	Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecologic Oncology, 2009, 113, 143-148.	0.6	336
3	Epithelialâ€“mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm. Journal of Cellular Physiology, 2007, 213, 581-588.	2.0	208
4	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. Journal of Cellular Biochemistry, 2011, 112, 2850-2864.	1.2	202
5	Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Phenotypes Facilitate Chemoresistance in Recurrent Ovarian Cancer. Current Cancer Drug Targets, 2010, 10, 268-278.	0.8	201
6	An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics, 2003, 3, 1980-1987.	1.3	193
7	Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors. PLoS ONE, 2012, 7, e46858.	1.1	188
8	Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Molecular Cancer, 2013, 12, 24.	7.9	179
9	Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. American Journal of Physiology - Cell Physiology, 2006, 290, C1532-C1542.	2.1	173
10	Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. International Journal of Cancer, 2007, 120, 2426-2434.	2.3	151
11	Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Seminars in Cancer Biology, 2018, 53, 265-281.	4.3	127
12	Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. Journal of Pathology, 2003, 201, 229-237.	2.1	121
13	Role of Integrin Receptors for Fibronectin, Collagen and Laminin in the Regulation of Ovarian Carcinoma Functions in Response to a Matrix Microenvironment. Clinical and Experimental Metastasis, 2005, 22, 391-402.	1.7	117
14	Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer, 2014, 14, 317.	1.1	105
15	Î±2Î²1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. Journal of Carcinogenesis, 2007, 6, 11.	2.5	103
16	Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer. ACS Applied Materials & Interfaces, 2018, 10, 25174-25185.	4.0	102
17	Î±_vÎ²₆Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer. Journal of Histochemistry and Cytochemistry, 2002, 50, 1371-1379.	1.3	94
18	Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics, 2005, 5, 4625-4636.	1.3	94

#	Article	IF	Citations
19	Direct integrin Î±vÎ²6-ERK binding: implications for tumour growth. Oncogene, 2002, 21, 1370-1380.	2.6	90
20	Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance. Journal of Cellular Biochemistry, 2013, 114, 21-34.	1.2	90
21	Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 186.	3.5	77
22	Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. Molecular Aspects of Medicine, 2014, 39, 110-125.	2.7	72
23	Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Frontiers in Oncology, 2014, 4, 75.	1.3	62
24	Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment. Cancer Microenvironment, 2012, 5, 83-93.	3.1	59
25	Association between ?v?6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. Journal of Cellular Biochemistry, 2002, 84, 675-686.	1.2	58
26	Strategies for revealing lower abundance proteins in two-dimensional protein maps. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 815, 39-50.	1.2	58
27	Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. Journal of Ovarian Research, 2012, 5, 37.	1.3	52
28	Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of Î±6Î²1 integrin. International Journal of Biochemistry and Cell Biology, 2009, 41, 1034-1045.	1.2	47
29	Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 2020, 9, 719.	1.8	43
30	Cell-Free 59 kDa Immunoreactive Integrin-Linked Kinase. Clinical Cancer Research, 2004, 10, 2415-2420.	3.2	42
31	Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Scientific Reports, 2016, 6, 30061.	1.6	33
32	Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer. Oncotarget, 2018, 9, 16599-16618.	0.8	27
33	A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer. Molecular Cancer, 2015, 14, 152.	7.9	26
34	2D-PAGE of ovarian cancer: Analysis of soluble and insoluble fractions using medium-range immobilized pH gradients. Biochemical and Biophysical Research Communications, 2011, 406, 408-413.	1.0	23
35	Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics, 2003, 3, 288-298.	1.3	22
36	TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells. BMC Cancer, 2020, 20, 960.	1.1	21

#	Article	IF	Citations
37	Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFÎºB-mediated induction of MMP2. Cancer Letters, 2014, 354, 107-114.	3.2	20
38	Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling. Scientific Reports, 2017, 7, 46312.	1.6	18
39	Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer. Journal of Ovarian Research, 2013, 6, 5.	1.3	16
40	Coalition of Oct4A and Î²1 integrins in facilitating metastasis in ovarian cancer. BMC Cancer, 2016, 16, 432.	1.1	14
41	The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence. Cell Communication and Signaling, 2021, 19, 55.	2.7	14
42	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 450.	1.8	13
43	Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment. Frontiers in Oncology, 2021, 11, 796588.	1.3	12
44	Expression and localization of ÂvÂ6 integrin in extraplacental fetal membranes: possible role in human parturition. Molecular Human Reproduction, 2004, 10, 173-179.	1.3	11
45	Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer. Cancers, 2019, 11, 243.	1.7	10
46	Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. Journal of Ovarian Research, 2010, 3, 17.	1.3	9
47	Enhanced activation of STAT3 in ascites-derived recurrent ovarian tumors: inhibition of cisplatin-induced STAT3 activation reduced tumorigenicity of ovarian cancer by a loss of cancer stem cell-like characteristics. Journal of Cancer Stem Cell Research, 2015, 3, 1.	1.1	6
48	Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. Frontiers in Medicine, 0, 9, .	1.2	5
49	Distinct molecular signature of recurrent ovarian tumor cells isolated from the ascites of advanced-stage serous ovarian cancer patients. Journal of Cancer Stem Cell Research, 2014, 1, 1.	1.1	3
50	15 Role of Integrins in Ovarian Cancer. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 425-439.	0.0	0